Lv6
1690 积分 2021-07-16 加入
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
4天前
已完结
Advances in Targeted Therapy for Non-Small-Cell Lung Cancer: Current Progress and Future Directions
5天前
已完结
Rare molecular subtypes of lung cancer
5天前
已完结
Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)
5天前
已完结
Emerging Targets in Non-Small Cell Lung Cancer
5天前
已完结
Targeted Therapies in Non–Small Cell Lung Cancer
5天前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
15天前
已完结
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
15天前
已完结
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
15天前
已完结
Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial
15天前
已完结
皖公网安备34019202002308
